Empagliflozin in Patients with Chronic Kidney Disease

BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligib...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Main Authors: Herrington, William G., Staplin, Natalie, Wanner, Christoph, Green, Jennifer B., Hauske, Sibylle J., Emberson, Jonathan R., Preiss, David, Judge, Parminder, Mayne, Kaitlin J., Ng, Sarah Y.A., Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K., Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P., Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R., Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J., Baigent, Colin, Haynes, Richard
Formato: Artigo
Idioma:Inglês
Publicado: 2023
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614055/
https://ncbi.nlm.nih.gov/pubmed/36331190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2204233
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares